10.97
+1.20%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Guizhou Sanli Pharmaceutical Co
Its shares trade on Shanghai under the ticker 603439.SS. It has been listed since 28 April 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.70bn and net income of CN¥46.3m. At that date it held total assets of CN¥2.85bn and shareholders' equity of CN¥1.45bn.
GuiZhou SanLi Pharmaceutical Co., Ltd. manufactures, researches and develops modern Chinese medicine. The company is headquartered in Guiyang, Guizhou. The company went IPO on 2020-04-28. The firm's product lines cover various areas, including pediatrics, respiratory systems, cardio-cerebrovascular and gastroenterology. Its main products are Kaihoujian spray (Pediatric Use), Kaihoujian spray and Qiangli Gastrodia Elata Eucommia capsules. The Kaihoujian spray (Pediatric Use) and Kaihoujian spray are used for the treatment of respiratory and oral diseases, and the Qiangli Gastrodia Elata Eucommia capsule is used for the treatment of cardiovascular and cerebrovascular diseases. The firm mainly sells its products through specialized academic marketing.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Apr 2020
- Employees
- 1,557
- Website
- gz-sanli.com ↗
Leadership
Pay as last reported
- Mr. Hai ZhangChairman of the Board, since 2011CN¥551,500
- Mr. Qianfan ZhangVice Chairman of the Board, General Manager, Secretary of the Board, since 2016CN¥459,700
- Mr. Jueben WangVice Chairman of the Board, Deputy General Manager, since 2024
- Ms. Ke GuoChief Financial Officer, Deputy General Manager, Staff Elected Director, since 2020CN¥500,000
- Ms. Hongyu ZhangChief Financial Officer, since 2015CN¥466,900
- Mr. Li DengDeputy General Manager
- Mr. Zhanbiao LuoDeputy General Manager
- Mr. Yi WangDeputy General ManagerCN¥594,200
- Mr. Zhiyu YangDeputy General Manager
- Mr. Yuan YuDeputy General ManagerCN¥533,000
- Mr. Jiyang GuAssistant to Chairman of the Board
- Mr. Yongjian ShengDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- GuiZhou SanLi Pharmaceutical Co., Ltd. manufactures modern Chinese medicine in Guiyang.
- The firm employs 1,557 full-time staff members for its operations.
- Product lines cover pediatrics, respiratory systems, and cardio-cerebrovascular areas.
Weaknesses
- The company went public on 28 April 2020 via an IPO.
- Main products include Kaihoujian spray and Qiangli Gastrodia Elata Eucommia capsules.
- Sales rely mainly on specialized academic marketing strategies.
Opportunities
- Kaihoujian spray treats respiratory and oral diseases effectively.
- Qiangli Gastrodia Elata Eucommia capsule addresses cardiovascular and cerebrovascular diseases.
- Pediatric use of Kaihoujian spray expands therapeutic reach.
Threats
- Competitors in the pharmaceutical sector may offer similar treatments.
- Regulatory changes in China could impact modern Chinese medicine.
- Market shifts might affect specialized academic marketing effectiveness.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.